{"id":3965,"date":"2022-06-16T05:30:54","date_gmt":"2022-06-16T09:30:54","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/"},"modified":"2026-09-24T00:07:05","modified_gmt":"2026-09-24T04:07:05","slug":"gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/","title":{"rendered":"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022"},"content":{"rendered":"\nParis, France, le 16 juin 2022<\/strong>, 7h30 CEST<\/strong> \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui sa participation au congr\u00e8s EUNOS 2022, qui se tiendra du 20 au 23 juin \u00e0 Birmingham, au Royaume-Uni. Ce congr\u00e8s, le plus important en Europe pour les neuro-ophtalmologistes, donne \u00e0 GenSight l’occasion de discuter de ses donn\u00e9es cliniques et de ses r\u00e9cents d\u00e9veloppements avec la communaut\u00e9 des neuro-ophtalmologistes. La soci\u00e9t\u00e9 fait partie des sponsors de EUNOS et disposera d’un stand sur place.\n\n \n\nPatrick Yu-Wai-Man<\/strong>, MD, PhD, professeur d’ophtalmologie et consultant honoraire en neuro-ophtalmologie \u00e0 l’Universit\u00e9 de Cambridge, au Moorfields Eye Hospital<\/em> et \u00e0 l’Institut d’ophtalmologie de l’UCL, Royaume-Uni, fera une pr\u00e9sentation sur deux sujets relatifs \u00e0 la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL). Il pr\u00e9sentera d’abord les donn\u00e9es de l’essai de phase III REFLECT de GenSight et discutera de l’efficacit\u00e9 de l’approche th\u00e9rapeutique bilat\u00e9rale. Il \u00e9voquera \u00e9galement l’avenir du traitement de la NOHL.\n\n \n\n\u00ab\u00a0Les donn\u00e9es de suivi \u00e0 long terme des patients dans l’essai REFLECT illustrent l’effet durable du traitement et l’impact clair sur l’acuit\u00e9 visuelle des patients atteints de NOHL<\/em>\u00ab\u00a0, a-t-il d\u00e9clar\u00e9. \u00ab\u00a0Ces donn\u00e9es seront particuli\u00e8rement int\u00e9ressantes pour les m\u00e9decins \u00e0 la recherche d’un traitement efficace contre cette maladie mitochondriale c\u00e9citante<\/em>.\u00a0\u00bb\n\n \n\n15\u00e8me<\/sup> Congr\u00e8s annuel de EUNOS (Soci\u00e9t\u00e9 europ\u00e9enne de neuro-ophtalmologie<\/em>) – EUNOS 2022<\/strong>\n\n20-23 juin 2022 – Universit\u00e9 de Birmingham, Edgbaston, Birmingham, Royaume-Uni<\/em><\/strong>\n\n \n\n\u00ab\u00a0The Phase III REFLECT trial: efficacy of bilateral gene therapy for Leber Hereditary Optic Neuropathy (LHON) is maintained 2 years post administration\u00a0\u00bb<\/em>, pr\u00e9sent\u00e9 par Patrick Yu-Wai-Man<\/strong>, MD, PhD, Universit\u00e9 de Cambridge, Royaume-Uni (investigateur principal des \u00e9tudes RESCUE, REVERSE, RESTORE, REFLECT et REALITY\u00a0; coordinateur international de l\u2019\u00e9tude REVERSE).\n
    \n \t
  • Pr\u00e9sentation orale<\/em><\/li>\n \t
  • Free Papers 1<\/em><\/li>\n \t
  • Mardi 21 juin 2022, 14h00 BST<\/em><\/li>\n<\/ul>\n \n\n\u00ab\u00a0Future Treatment for Leber\u2019s hereditary optic neuropathy\u00a0\u00bb<\/em>, pr\u00e9sent\u00e9 par Patrick Yu-Wai-Man<\/strong>, MD, PhD, Universit\u00e9 de Cambridge, Royaume-Uni (investigateur principal des \u00e9tudes RESCUE, REVERSE, RESTORE, REFLECT et REALITY\u00a0; coordinateur international de l\u2019\u00e9tude REVERSE).\n
      \n \t
    • Pr\u00e9sentation orale<\/em><\/li>\n \t
    • Inherited Optic Neuropathies <\/em><\/li>\n \t
    • Mercredi 22 juin 2022, 15h00 BST <\/em><\/li>\n<\/ul>\n \n\nGenSight Biologics pr\u00e9sentera \u00e9galement les donn\u00e9es cliniques de GS010 (Lenadogene nolparvovec) lors du Global 7th<\/sup> Cell & Gene Therapy Summit<\/em>, du 19 au 21 juillet. Magali TAIEL<\/strong>, MD, Directrice M\u00e9dicale de GenSight Biologics, fera une pr\u00e9sentation intitul\u00e9e \u00ab\u00a0Development of GS010 gene therapy in Leber Hereditary Optic Neuropathy: Key learnings\u00a0\u00bb<\/em>.\n","protected":false},"excerpt":{"rendered":"

      Paris, France, le 16 juin 2022, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui sa participation au congr\u00e8s EUNOS 2022, qui se tiendra […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[73],"news-type":[76,77],"post-year":[],"class_list":["post-3965","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-gs010-lumevoq","news-type-corporate","news-type-conferences"],"acf":[],"yoast_head":"\nGenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 16 juin 2022, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui sa participation au congr\u00e8s EUNOS 2022, qui se tiendra […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-16T09:30:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:07:05+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/06\\\/16\\\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/06\\\/16\\\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022\",\"datePublished\":\"2022-06-16T09:30:54+00:00\",\"dateModified\":\"2026-09-24T04:07:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/06\\\/16\\\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\\\/\"},\"wordCount\":460,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/06\\\/16\\\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/06\\\/16\\\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\\\/\",\"name\":\"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-06-16T09:30:54+00:00\",\"dateModified\":\"2026-09-24T04:07:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/06\\\/16\\\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/06\\\/16\\\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2022\\\/06\\\/16\\\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022 - GenSight Biologics","og_description":"Paris, France, le 16 juin 2022, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui sa participation au congr\u00e8s EUNOS 2022, qui se tiendra […]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/","og_site_name":"GenSight Biologics","article_published_time":"2022-06-16T09:30:54+00:00","article_modified_time":"2026-09-24T04:07:05+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022","datePublished":"2022-06-16T09:30:54+00:00","dateModified":"2026-09-24T04:07:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/"},"wordCount":460,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/","name":"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2022-06-16T09:30:54+00:00","dateModified":"2026-09-24T04:07:05+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2022\/06\/16\/gensight-biologics-annonce-sa-participation-et-la-presentation-de-donnees-cliniques-de-gs010-a-eunos-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce sa participation et la pr\u00e9sentation de donn\u00e9es cliniques de GS010 \u00e0 EUNOS 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3965"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3965\/revisions"}],"predecessor-version":[{"id":6873,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3965\/revisions\/6873"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3965"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3965"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3965"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3965"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}